Welcome to our dedicated page for Blueprint Medicines SEC filings (Ticker: BPMC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Blueprint Medicines Corporation (BPMC) SEC filings, offering a regulatory view of the company’s evolution as a global biopharmaceutical business focused on allergy/inflammation and oncology/hematology. Through these documents, readers can review how Blueprint Medicines reports on its commercial activities with AYVAKIT/AYVAKYT (avapritinib), its pipeline programs in systemic mastocytosis and mast cell-mediated diseases, and its financial position.
Key filings for BPMC include annual reports on Form 10-K and quarterly reports on Form 10-Q, which historically have detailed product revenue from AYVAKIT/AYVAKYT, research and development expenses, selling, general and administrative expenses, and information about the company’s cash, cash equivalents and investments. Current reports on Form 8-K capture material events, such as the June 20, 2025 filing describing the company’s annual meeting of stockholders and voting results, and other significant corporate developments.
For corporate structure and trading status, a notable document is the Form 15 (15-12G) filed on July 28, 2025. In this filing, Blueprint Medicines certified the termination of registration of its common stock under Section 12(g) of the Securities Exchange Act of 1934 and the suspension of its duty to file reports under Sections 13 and 15(d). The Form 15 notes that the approximate number of holders of record as of the certification date was one, reflecting the company’s transition following its acquisition agreement with Sanofi.
Investors researching BPMC SEC filings can use this page to locate historical 10-K and 10-Q reports for detailed financial and risk disclosures, Form 4 insider transaction reports where available, and 8-K filings describing governance matters and other material events. Stock Titan’s platform enhances this information with AI-powered summaries that explain the contents of lengthy filings, highlight key changes, and help users quickly identify items such as revenue trends, major agreements, capital structure changes and governance decisions. Real-time updates from EDGAR ensure that new BPMC-related filings, including acquisition-related documents and deregistration notices, are surfaced promptly with concise AI insights.
Blueprint Medicines Corp. (NASDAQ: BPMC) filed Amendment No. 1 to its Schedule 14D-9, updating shareholders on Sanofi’s $129.00-per-share cash tender offer plus a non-transferable contingent value right (CVR) worth up to an additional $6.00 per share. The amendment provides supplemental disclosure on (i) financial advisor valuation work and (ii) regulatory and legal developments.
Financial advisor analyses. Centerview’s discounted cash-flow (DCF) generated an implied equity value range of $115.80-$148.50 per share, while Jefferies’ DCF showed $112.50-$143.65. Both were benchmarked against the implied consideration of approximately $131.00 (cash + CVR midpoint). Centerview’s precedent-premium study implied $136.80-$187.50 per share. Historical trading over the prior 52 weeks ranged $79.22-$120.50; 21 sell-side price targets ranged $83-$167 (median $130).
Regulatory clearances achieved. The U.S. HSR waiting period expired on 9 July 2025, satisfying a key closing condition. Clearance milestones were also reached in Austria (8 July 2025), Germany (30 June 2025) and Italy (25 June 2025, Golden Power exemption). These approvals materially reduce antitrust risk for the transaction.
Legal proceedings. Two shareholder suits (Williams and Phillips) filed in New York allege the Schedule 14D-9 is materially incomplete; 12 additional demand letters request further disclosure. The company denies wrongdoing but voluntarily provided the new disclosures to mitigate delay or expense.
Bottom line. The amendment does not change economic terms, but confirms multiple regulatory approvals and reveals valuation ranges that largely bracket the $131 offer, supporting fairness. Litigation represents a manageable but ongoing risk.
Blueprint Medicines Corporation (BPMC) director Jeffrey W. Albers received a significant equity grant on June 18, 2025. The transaction involved 3,902 restricted stock units (RSUs) awarded at a price of $128.12 per share.
Key details of the RSU grant:
- Vesting occurs 100% on the earlier of June 18, 2026, or the next annual stockholder meeting
- Each RSU represents one share of common stock
- Following the transaction, Albers directly owns 150,532 shares
This Form 4 filing, signed by attorney-in-fact Melissa Masse on June 23, 2025, reflects standard director compensation practices and demonstrates continued alignment between board members and shareholder interests through equity-based compensation.
Blueprint Medicines Corp (BPMC) Director Mark Alan Goldberg received a grant of 3,902 restricted stock units (RSUs) on June 18, 2025, valued at $128.12 per share. Following this transaction, Goldberg directly owns 22,156 shares of common stock.
Key details of the RSU grant:
- Vesting occurs 100% on the earlier of June 18, 2026, or the next annual stockholder meeting
- Each RSU represents the right to receive one share of common stock
- Total value of granted RSUs: approximately $500,000
This Form 4 filing, executed by attorney-in-fact Melissa Masse on June 23, 2025, represents standard equity compensation for a board member, aligning director interests with shareholders through stock ownership.